M&A - Adage Capital Management, L.P.

Form Type: SCHEDULE 13D/A

Filing Date: 2025-06-20

Corporate Action: Merger

Type: Update

Accession Number: 000090266425002765

Filing Summary: This document is Amendment No. 1 to the Schedule 13D previously filed with the SEC regarding the ordinary shares of Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.). The amendment is filed due to changes in the outstanding ordinary shares resulting from the completion of a merger on June 13, 2025. As a consequence of this merger, the Reporting Persons, including Adage Capital Management, L.P., no longer beneficially own more than 5% of the ordinary shares. Additionally, the amendment is the final update to inform of the exit from the reporting obligations associated with the previous ownership, following a reverse stock split and redomestication on June 16, 2025. The total ordinary shares outstanding were adjusted to 13,892,562 after the stock split, and the month leading to this amendment showed no transactions in the ordinary shares by the Reporting Persons.